Lv41
594 积分 2024-03-18 加入
Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies
4天前
已完结
Potentiating CAR-T-cell function in the immunosuppressive tumor microenvironment by inverting the TGF-β signal
10天前
已完结
Correlation of IL-10 and IL18 with the development of liver cirrhosis associated with hepatitis B virus infection: A systematic review
10天前
已完结
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
16天前
已完结
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
16天前
已关闭
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
16天前
已完结
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
17天前
已完结
CTLA-4 tail fusion enhances CAR-T antitumor immunity
1个月前
已完结
A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity
1个月前
已完结
Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells
1个月前
已完结
皖公网安备34019202002308
